7500 Participants Enrolled!

REPRIEVE

Randomized Trial to Prevent Vascular Events in HIV

View this email in your browser
WE DID IT!!!

7500 Participants Enrolled!!!

Congratulations to the University of Southern California CRS, Site 1201 for enrolling the 7500th participant!

From REPRIEVE Leadership:

This is a tremendous accomplishment for REPRIEVE and we want to thank every site team for working so incredibly hard to help reach this major milestone.

REPRIEVE is the largest randomized controlled trial in people with HIV as well as the largest ACTG study to date. This study is a success because of the dedication from sites in 11 countries around the world and equally important is the dedication of REPRIEVE participants. We would also like to recognize the collaboration of our
supporters, the NHLBI, NIAID, Kowa Pharmaceuticals America, Inc. and Gilead Sciences, Inc.

We look forward to working with you during the next phase of REPRIEVE and together we will continue to make REPRIEVE a success!

Sincerely,
Dr. Steven Grinspoon and Dr. Pamela Douglas, Co-Principal Investigators of the Clinical Coordinating Center
Dr. Udo Hoffmann and Dr. Heather Ribaudo, Co-Principal Investigators of the Data Coordinating Center

As a reminder, the study has closed to screening as of today (Thursday, February 7, 2019) at 9:00 AM EST.

Accrual of participants in screening must be completed within 45 days from today (Thursday, February 7, 2019) and not exceed the protocol defined screening period. Please be aware, enrollment cannot exceed 7575 participants. Sites will receive further notification about the date of closure to accrual.

Please continue to email the team at actg.corea5332@fstrf.org if there are any questions regarding the management of participants still on study.
7500 Participants Enrolled!

www.reprievetrial.org

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

This email was sent to <<Email Address>>

why did I get this? unsubscribe from this list update subscription preferences

Massachusetts General Hospital · 5 Longfellow Place · Boston, MA 02214 · USA